Castleark Management’s RxSight RXST Stock Holding History

Castleark Management’s Portfolio RXST Stock Details RXST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-49,810	Closed	-$3M	–	301
2024 Q2	$3M	Buy	+49,810	New	+$2.85M	0.12%	153

Other funds holding RXST

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Castleark Management's RXST Position: Q3 2024 in Review

Castleark Management sold out of RxSight (RXST) in Q3 2024, closing a stake of 49,810 shares — an estimated $3M sold.

Castleark Management first reported a position in RXST in Q2 2024 and held it in 1 quarter. The position peaked at $3M in Q2 2024. 214 funds tracked by Wall St. Rank hold RXST as of Q3 2024.

Castleark Management reported no remaining RxSight position as of Q3 2024 after selling out during the quarter.
Castleark Management sold 49,810 RxSight shares in Q3 2024, an estimated $3M.
Castleark Management first reported a position in RxSight in Q2 2024 and held it in 1 quarter.
Castleark Management's RxSight position peaked at $3M in Q2 2024.
214 funds tracked by Wall St. Rank held RxSight as of Q3 2024.

Based on Castleark Management's 13F filing for Q3 2024, filed 15 Nov 2024.